Washington [US], March 9 (ANI): Pharmaceutical company Pfizer on Tuesday (local time) stated that it has started the Phase 2/3 clinical study to evaluate the safety and efficacy of its COVID-19 oral treatment in the pediatric population at risk of progression to severe disease.

"Today, we announced the start of a Phase 2/3 study to evaluate the safety and efficacy of our COVID-19 oral treatment in pediatric participants at risk of progression to severe disease. We are eager to address the need for treatment in this important population," it said in a tweet.

Also Read | Russia-Ukraine War: Power Cut At Ukraine’s Chernobyl Nuclear Plant.

The pharmaceutical company further said Pfizer's oral treatment is not approved but is authorized for emergency use by the Food and Drug Administration (FDA) to treat mild-to-moderate COVID-19 in high-risk patients 12 plus, weighing at least 40 kg, with positive results of SARS-CoV-2 viral testing. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)